HALIFAX, Sept. 27 /CNW/ - ImmunoVaccine Technologies Inc. (IVT) finalizes
an important step in its progress with the last appointment to its scientific
advisory board (SAB), international oncology expert, Dr. Neil Berinstein.
Dr. Berinstein is the Global Head of the Cancer Vaccine Program at sanofi
pasteur, and a professor at the University of Toronto's Department of
Medicine. He has a long track record in fundamental research and has a
significant publication record in the area of normal and malignant B cell
biology, including articles, abstracts and book chapters on immunotherapeutic
approaches for cancer including cancer vaccines. He was recently appointed
vice-president of the Sabin Institute Cancer vaccine consortium.
Dr. Berinstein received an MD from the University of Manitoba, and completed
training programs at the University of Toronto in Internal Medicine and
Medical Oncology. Following this, he spent four years as a post-doctoral
fellow in Dr. Ron Levy's Lab at Stanford University working in the area of
immunotherapy for cancer.
"IVT has very promising science," remarked Dr. Berinstein. "Their work is
particularly interesting to me, and my commitment to new immunotherapeutic
approaches for patients with cancer. "
ImmunoVaccine Technologies Inc. has been actively recruiting members to
its SAB in preparation for its Phase I clinical trials, and sees this final
appointment as a major stepping stone to that goal.
"This final appointment is one of the last steps before our Phase I
clinical trials," said Dr. Martin Kast, chair of the scientific advisory
board. "Dr. Berinstein's experience and insight are reflective of the quality
of professionals that our exciting projects have attracted," continued Kast.
"Dr. Berinstein is a valuable addition to the team, and represents a
pivotal point in our ongoing plan to introduce our patented vaccine platform,"
commented Dr. Randal Chase, president and CEO of IVT.
ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company
focused on the commercialization of its patented VacciMax(R) platform.
VacciMax(R) is a novel technology that can aid the development of new vaccines
in human health applications with potential for both therapeutic cancer
applications and preventative infectious disease vaccines. The opportunities
for market applications and medical benefits are broad, and are currently
being applied to cervical cancer, with potential for melanoma, breast,
prostate and colon cancer treatments, as well as prevention therapies for
influenza and other infectious diseases. www.immunovaccine.com
For further information:
For further information: Jennifer Ayotte, Communications, (902) 423-6610
x 315, email@example.com; Brian Lowe, Chief Operating Officer,
(902) 492-1819, firstname.lastname@example.org